Loading company
Cryo Cell International Inc.
CCEL · NYSE · ·
Next earnings: October 21, 2026
$4.15-2.2%Sep 28 close
- 1M
- +3.6%
- 6M
- +21.6%
- 1Y
- -10.7%
- 5Y
- -57.4%
Cryo Cell International Inc. is the 40th largest of 44 graded companies. Showing 5 of them, including CCEL itself. 5 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Guardian Pharmacy Services, Inc.GRDN | A | — | $1.5B | 4.5% | $86.8M | — |
| HCA Healthcare, Inc.HCA | A | $95.7B | $76.4B | 8.9% | $7.9B | 14.86 |
| Tenet Healthcare Corp.THC | A+ | $20.8B | $21.8B | 14.6% | $3B | 9.94 |
| Encompass Health CorporationEHC | B+ | $12.2B | $6.2B | 10.0% | $413.4M | 20.13 |
| Cryo-Cell International, Inc.CCEL | B | $33.4M | $31.1M | -7.9% | $6.1M | — |
39 more medical care facilities companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Cryo Cell International Inc. on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
CCEL · NYSE · ·
Next earnings: October 21, 2026
$4.15-2.2%Sep 28 close